Fitoterapia · 2025
Xin Sheng Hua Granule ameliorate chemotherapy-induced blood deficiency syndrome through ihibiting JAK1/STAT1 pathway activation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luo Jie, Zhu Pei-Feng, Li Xiao-Li, Huang Jun-Ying, Jin Qiong, Zhang Xi, Liu Lu
Аннотация
BACKGROUND: As a classic prescription for postpartum diseases in traditional Chinese medicine prescriptions, Xin Sheng Hua Granule (XSHG) exerts pharmacological activities such as promoting blood circulation and removing blood stasis. However, its mechanism remains incompletely elucidated to date.
PURPOSE: To analyze the nascent particles by Ultra Performance Liquid Chromatography-Quadrupole-Time-of-Flight/Mass Spectrometry (UPLC-Q-TOF/MS), to explore the effectiveness of XSHG on blood deficiency syndrome, and to clarify its material basis and potential mechanism.
METHODS: The chemical composition of nascent particles was qualitatively analyzed by UPLC-Q-TOF/MS. The mechanism of XSHG in alleviating blood deficiency syndrome was predicted using network pharmacology, and its effects were further investigated by establishing a rat model of blood deficiency. The expression of related proteins in the Janus Kinase 1 (JAK1)/ Signal Transducer and Activator of Transcription 1 (STAT1) signaling pathway and inflammatory proteins were examined using the methods such as Hematoxylin and Eosin (H&E), Real-Time Reverse Transcription PCR (qRT-PCR), Immunohistochemistry (IHC) and Western Blotting (WB) to elucidate the underlying protective mechanisms of XSHG in mitigating Blood Deficiency Syndrome (BDS).
RESULTS: A total of 109 compounds were identified from the nascent particles. Network pharmacology research reveals that the mechanism of XSHG in the treatment of BDS may be related to the JAK1/STAT1 signaling pathway. In experiments, XSHG significantly protected mice against Cyclophosphamide (CTX) and APH-induced BDS by attenuating spleen histological changes and activities of Erythropoietin (EPO), (Granulocyte-Macrophage Colony-Stimulating Factor) GM-CSF. The BDS with CTX and APH-induced was inhibited by XSHG as confirmed by the inhibition of Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 beta (IL-1β) and Interleukin-6 (IL-6) production. Furthermore, CTX and APH-induced expression of JAK1 and STAT1, and activation of nuclear factor-κB (NF-κB) were significantly suppressed by XSHG.
CONCLUSION: This study revealed the chemical composition of XSHG and elucidated the great benefit of XSHG in the treatment of CTX combined with Acetylphenylhydrazine (APH)-induced BDS. This study explores the mechanism of XSHG from the perspective of JAK1/STAT1 signaling pathway for the first time, and provides a scientific basis for further study of XSHG and BDS.
PURPOSE: To analyze the nascent particles by Ultra Performance Liquid Chromatography-Quadrupole-Time-of-Flight/Mass Spectrometry (UPLC-Q-TOF/MS), to explore the effectiveness of XSHG on blood deficiency syndrome, and to clarify its material basis and potential mechanism.
METHODS: The chemical composition of nascent particles was qualitatively analyzed by UPLC-Q-TOF/MS. The mechanism of XSHG in alleviating blood deficiency syndrome was predicted using network pharmacology, and its effects were further investigated by establishing a rat model of blood deficiency. The expression of related proteins in the Janus Kinase 1 (JAK1)/ Signal Transducer and Activator of Transcription 1 (STAT1) signaling pathway and inflammatory proteins were examined using the methods such as Hematoxylin and Eosin (H&E), Real-Time Reverse Transcription PCR (qRT-PCR), Immunohistochemistry (IHC) and Western Blotting (WB) to elucidate the underlying protective mechanisms of XSHG in mitigating Blood Deficiency Syndrome (BDS).
RESULTS: A total of 109 compounds were identified from the nascent particles. Network pharmacology research reveals that the mechanism of XSHG in the treatment of BDS may be related to the JAK1/STAT1 signaling pathway. In experiments, XSHG significantly protected mice against Cyclophosphamide (CTX) and APH-induced BDS by attenuating spleen histological changes and activities of Erythropoietin (EPO), (Granulocyte-Macrophage Colony-Stimulating Factor) GM-CSF. The BDS with CTX and APH-induced was inhibited by XSHG as confirmed by the inhibition of Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 beta (IL-1β) and Interleukin-6 (IL-6) production. Furthermore, CTX and APH-induced expression of JAK1 and STAT1, and activation of nuclear factor-κB (NF-κB) were significantly suppressed by XSHG.
CONCLUSION: This study revealed the chemical composition of XSHG and elucidated the great benefit of XSHG in the treatment of CTX combined with Acetylphenylhydrazine (APH)-induced BDS. This study explores the mechanism of XSHG from the perspective of JAK1/STAT1 signaling pathway for the first time, and provides a scientific basis for further study of XSHG and BDS.